CGON

CG Oncology, Inc. - Common stock (CGON)

About CG Oncology, Inc. - Common stock (CGON)

CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. It offers cretostimogene, a product initially in clinical development for the treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The company was founded by Alex Yeung and Paul A. DeRidder on September 24, 2010 and is headquartered in Irvine, CA.

Details

Daily high

$26.94

Daily low

$25.81

Price at open

$26.08

52 Week High

$40.47

52 Week Low

$14.80

Market cap

2.1B

Dividend yield

0.00%

Volume

704,925

Avg. volume

848,419

P/E ratio

-19.41

CG Oncology, Inc. - Common stock News